Nectin-4 expression
Nectin-4 is expressed by almost every urothelial cancer, so enfortumab vedotin is given without a test. Nectin-4 amplification is being studied as a marker of especially strong response.
Overview
Enfortumab vedotin (Padcev) is labelled alone and with pembrolizumab for locally advanced or metastatic urothelial cancer with no Nectin-4 requirement; the pivotal EV-201 and EV-301 trials enrolled without testing after screening showed near-universal expression. Retrospective work links NECTIN4 amplification to higher response rates; a Nectin-4 PET tracer is in early trials. No approval or guideline sets a threshold.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · Nectin-4 is an adhesion protein plentiful on bladder cancer cells, used as the docking site for the ADC enfortumab vedotin.
Enfortumab vedotin does not need a Nectin-4 test; the antigen is present in nearly all bladder cancers. Research is looking at whether tumours with extra copies of the Nectin-4 gene respond even better, but that is not part of routine care.
Written only from the label or guideline text cited on this page. Not medical advice; your own report and the reading your team gives it come first.
The label names the antigen in the drug's description but does not require it to be measured before treatment; no approval threshold exists for this readout.
“PADCEV is a Nectin-4-directed antibody and microtubule inhibitor conjugate”
PADCEV prescribing information (DailyMed)No approval uses this readout as a threshold.
Matched on the name and aliases of the readout in the title, setting and summary of each trial; a match is a mention, not proof the readout was an entry criterion.
- NCT06265727A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
- NCT07299747Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors
- NCT05163041Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression
- NCT04561362Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
Similar pages
not linked directly; found by shared links- BiomarkerCEACAM5 expression
Shares TROP2 expression and the tags biomarker, surface-antigen, no-threshold.
- BiomarkerB7-H3 (CD276) expression
Shares the tags biomarker, surface-antigen, no-threshold.
- BiomarkerBCMA expression
Shares the tags biomarker, surface-antigen, no-threshold.
- BiomarkerCD38 expression
Shares the tags biomarker, surface-antigen, no-threshold.
- BiomarkerDLL3 expression
Shares the tags biomarker, surface-antigen, no-threshold.
- BiomarkerFcRH5 expression
Shares the tags biomarker, surface-antigen, no-threshold.
- BiomarkerGPRC5D expression
Shares the tags biomarker, surface-antigen, no-threshold.
- BiomarkerHER3 expression
Shares the tags biomarker, surface-antigen, no-threshold.